Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2013 - 2026)

Ironwood Pharmaceuticals has disclosed Non-Current Debt across 11 years of filings, most recently posting $385.0 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $385.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $385.0 million (changed 0.0% YoY), and the FY2025 annual result was $385.0 million, changed 0.0% from the prior year.
• Non-Current Debt came in at $385.0 million for Q1 2026 at Ironwood Pharmaceuticals, roughly flat from $385.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $425.0 million in Q2 2024 to a low of $275.0 million in Q1 2024.
• The 4-year median for Non-Current Debt is $385.0 million (2024), against an average of $369.6 million.
• Peak annual rise in Non-Current Debt reached 40.0% in 2025, while the deepest fall reached 9.41% in 2025.
• Ironwood Pharmaceuticals' Non-Current Debt stood at $300.0 million in 2023, then rose by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025, then changed by 0.0% to $385.0 million in 2026.
• The last three Non-Current Debt figures came in at $385.0 million (Q1 2026), $385.0 million (Q4 2025), and $385.0 million (Q3 2025), per Business Quant data.